Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1650550-25-6
2. Ag-221 Mesylate
3. Enasidenib Mesilate
4. Enasidenib Methanesulfonate
5. Enasidenib (mesylate)
6. Uf6pc17xav
7. Enasidenib Mesylate [usan]
8. Cc-90007
9. 1650550-25-6 (mesylate)
10. Enasidenib Mesylate (usan)
11. 2-propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, Methanesulfonate (1:1)
12. 2-methyl-1-[4-(6-trifluoromethyl-pyridin-2-yl)-6-(2-trifluoromethyl-pyridin-4-ylamino)-[1,3,5]triazin-2-ylamino]-propan-2-ol Mesylate
13. Methanesulfonic Acid;2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
14. Unii-uf6pc17xav
15. Idhifa (tn)
16. Chembl3989931
17. Enasidenib Mesylate [mi]
18. Schembl16448052
19. Dtxsid501027943
20. Bcp26166
21. Ex-a1972
22. Enasidenib Mesylate [who-dd]
23. Hy-18690a
24. S4929
25. Enasidenib Mesylate; Ag-221 Mesylate
26. At36098
27. Cs-7541
28. Enasidenib Mesylate [orange Book]
29. Ac-31319
30. D11044
31. Q27291054
32. 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)- 6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin- 2-yl)amino)propan-2-ol Methanesulfonate
| Molecular Weight | 569.5 g/mol |
|---|---|
| Molecular Formula | C20H21F6N7O4S |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 17 |
| Rotatable Bond Count | 6 |
| Exact Mass | 569.12799232 g/mol |
| Monoisotopic Mass | 569.12799232 g/mol |
| Topological Polar Surface Area | 172 Ų |
| Heavy Atom Count | 38 |
| Formal Charge | 0 |
| Complexity | 727 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
ABOUT THIS PAGE
86
PharmaCompass offers a list of UNII-UF6PC17XAV API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right UNII-UF6PC17XAV manufacturer or UNII-UF6PC17XAV supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred UNII-UF6PC17XAV manufacturer or UNII-UF6PC17XAV supplier.
PharmaCompass also assists you with knowing the UNII-UF6PC17XAV API Price utilized in the formulation of products. UNII-UF6PC17XAV API Price is not always fixed or binding as the UNII-UF6PC17XAV Price is obtained through a variety of data sources. The UNII-UF6PC17XAV Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Enasidenib (mesylate) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Enasidenib (mesylate), including repackagers and relabelers. The FDA regulates Enasidenib (mesylate) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Enasidenib (mesylate) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Enasidenib (mesylate) supplier is an individual or a company that provides Enasidenib (mesylate) active pharmaceutical ingredient (API) or Enasidenib (mesylate) finished formulations upon request. The Enasidenib (mesylate) suppliers may include Enasidenib (mesylate) API manufacturers, exporters, distributors and traders.
Enasidenib (mesylate) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Enasidenib (mesylate) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Enasidenib (mesylate) GMP manufacturer or Enasidenib (mesylate) GMP API supplier for your needs.
A Enasidenib (mesylate) CoA (Certificate of Analysis) is a formal document that attests to Enasidenib (mesylate)'s compliance with Enasidenib (mesylate) specifications and serves as a tool for batch-level quality control.
Enasidenib (mesylate) CoA mostly includes findings from lab analyses of a specific batch. For each Enasidenib (mesylate) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Enasidenib (mesylate) may be tested according to a variety of international standards, such as European Pharmacopoeia (Enasidenib (mesylate) EP), Enasidenib (mesylate) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Enasidenib (mesylate) USP).
